DNA

Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --…

2 months ago

Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the…

2 months ago

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30…

2 months ago

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer…

2 months ago

Latin America Accelerates Health Data Interoperability With openEHR: A Regional Model for Global Digital Health Transformation

New Black Book Research survey reveals Brazil, Mexico, Chile, and Colombia leading rapid adoption of openEHR frameworks as Doug Brown…

2 months ago

New Study Showed Unnecessary Burden From Continued Monitoring of Alloimmunized Pregnancies With Antigen-Negative Fetuses

New research demonstrates that monitoring with titers frequently leads to burdensome and unnecessary monitoring for pregnancies not at risk of…

2 months ago

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities 

Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology…

2 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD…

2 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with…

2 months ago

Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting

Announcement no. 09/2025Inside information   Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting …

2 months ago